Shots: Arrowhead to receive $40M up front and is eligible to receive ~$660M as potential development, regulatory & commercial milestones, and is further eligible to receive royalties on net product […]readmore
Tags : License Agreement
Shots: Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company […]readmore
Shots: The Phenomix’s MyPhenome test utilize phenotype-driven multi-omics technology to analyze genomics, metabolomics, and hormone levels and use AI-driven algorithmic tool to identify four specific obesity phenotypes, giving doctors the […]readmore
Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. […]readmore
Shots: Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with […]readmore
Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an […]readmore
Shots: Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in […]readmore
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a […]readmore
Shots: Innovet to receive non-refundable sum of $500,000 which is payable on the effective date of the agreement and a second non-refundable sum of $250,000 which is payable on the […]readmore
Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a […]readmore